Pfizer and Nektar Therapeutics have reached an agreement settling their contractual issues regarding Exubera and Nektar’s new inhaled insulin product, which is currently in Phase I. Nektar will receive a one-time payment of $135 million from Pfizer to end all obligations under existing agreements relating to Exubera and the new product. Also, if Nektar finds a new partner, Pfizer will transfer its remaining rights and all economic benefits for Exubera and the new product. This would inc...